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Cationic antimicrobial peptides (AMPs) and host defense peptides (HDPs) show vast
potential as peptide-based drugs. Great effort has been made in order to exploit their
mechanisms of action, aiming to identify their targets as well as to enhance their activity
and bioavailability. In this review, we will focus on both naturally occurring and designed
antiviral and antitumor cationic peptides, including those here called promiscuous, in which
multiple targets are associated with a single peptide structure. Emphasis will be given to
their biochemical features, selectivity against extra targets, and molecular mechanisms.
Peptides which possess antitumor activity against different cancer cell lines will be
discussed, as well as peptides which inhibit virus replication, focusing on their applications
for human health, animal health and agriculture, and their potential as new therapeutic
drugs. Moreover, the current scenario for production and the use of nanotechnology as
delivery tool for both classes of cationic peptides, as well as the perspectives on improving
them is considered.
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INTRODUCTION
Antimicrobial peptides (AMPs) are natural peptides found in
microorganisms, plants, and animals, and are considered the evo-
lutionarily conserved effectors in innate immunity (Hancock and
Chapple, 1999; Hancock and Sahl, 2006). These peptides can
be classified by physical–chemical properties such as cationic,
anionic, hydrophilic, and amphipathic (Peter et al., 2010).
Although they are diverse in length and sequence, two physical-
chemical features are often the hallmarks of these molecules:
they are cationic, often ranging from +2 to +7 at pH 7, and
amphipathic, therefore their stereogeometry confers relatively
polarized hydrophilic and hydrophobic facets (Nguyen et al.,
2011). Despite their structural conservation, they have a broad
spectrum of activity such as antibacterial (Okubo et al., 2012;
Tavares et al., 2012), antioxidative (Power et al., 2013), antihyper-
tensive (Escudero et al., 2012), antifungal (Mandal et al., 2013),
antiviral (Findlay et al., 2013), antitumor as well as modulation of
the immune response (Silva et al., 2012). The modulation of the
immune response role is specific to a group of peptides named
host defense peptides (HDPs). Moreover, multiple functions may
be associated with a single peptide according to the concept of
promiscuity. They may act over different targets, therefore pre-
senting different functions depending on their physical-chemical
(namely pure promiscuity) or on their amino acid modifica-
tion (namely family promiscuity) (Franco, 2011). These features
confer to AMPs and HDPs many physiological advantages over
other molecules for application in the field of drug develop-
ment. As is summarized here, many AMPs and HDPs isolated
from a wide variety of organisms including mammals, amphib-
ians, insects, plants, and bacteria have been reported to have
antiviral and/or antitumor activities. This review comprises their
mechanisms of action and targets, as well as their potential as
new therapeutic strategies to combat both viruses and malignant
cells.
CATIONIC ANTITUMOR PEPTIDES
Cancer has become a major concern in relation to human mor-
bidity and mortality. All types of cancer are characterized by
irregular cell growth originating from a small number of inherited
or environmentally-stimulated genetic mutations (Renan, 1993).
Many strategies have been adopted to combat the propagation
of cancer cells and their elevated growth such as chemotherapy,
surgery, and radiation (Wang and Zhang, 2013). These typical
procedures have often been revealed to be non-specific for can-
cer cells (Yang et al., 2013), additionally acting on the cell division
of healthy cells, consequently impairing the restoration of normal
tissues (Smith et al., 2000). Antitumor drugs are subject to differ-
ences in absorption, metabolism, and target tissue, which can be
particular to each patient; moreover, tumors can be positioned
in places into which drug penetration is impaired or possibly
sheltered by restricted environments due to amplified hydrostatic
pressure in the tissue or modified tumor vasculatures (Szakacs
et al., 2006). Furthermore, the intrinsic or acquired drug resis-
tance is considered the widespread cause for tumor recurrence
(Szakacs et al., 2006).
Acknowledging the limitations of these currently available
therapies, researchers have been encouraged to seek novel anti-
cancer agents with only one exclusive mechanism of action
(Szakacs et al., 2006; Hoskin and Ramamoorthy, 2008). In this
context, natural AMPs from different sources and their synthetic
analogs have been the basis for a number of studies performed to
discover new therapies for treating malignant cells (Table 1).
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Table 1 | Cationic antitumor peptides from different sources, their application, and their mechanisms of action.
Peptides Source Group Application Mechanism of action References
AGAP Buthus martensii Insect Lymphoma, leukemia, human
malignant glioma, human colon
cancer
Cell cycle arrest Cao et al., 2010; Zhao
et al., 2011; Gu et al.,
2013
Alloferon Calliphora vicina Insect Leukemia Induces NK and
IFN—Immune-modulatory
Chernysh et al., 2002
Aplidine Aplidium albicans Tunicate Melanoma, non-small cell lung,
prostate, ovarian, colorectal
Multifactorial apoptosis
inducer/cell cycle
arrest/inhibition of protein
synthesis
Faivre et al., 2005
Apratoxin A Lyngbya
majuscula
Cyanobacteria HeLa (human cervical cancer) Cell cycle arrest Ma et al., 2006
Arenastatin A Dysidia arenaria Sponge Human KB carcinoma NR Kobayashi et al., 1994
Aurein 1.2 Litoria raniformis Frog Leukaemia, lung, colon, CNS,
melanoma, ovarian, renal
prostate, breast
Barrel stave mechanism Rozek et al., 2000
BMAP-27
BMAP-28
Bos taurus Mammal Leukemia, human
erythromyeloblastoid leukemia,
human leukemic monocyte
lymphoma
Influx of Ca2+
DNA fragmentation
Increase membrane
permeabilization
Risso et al., 1998, 2002
Brevinin-2R Rana ridibunda Frog Leukemia, lymphoma, colon
carcinomas, fibrosarcoma, breast
adenocarcinoma, lung carcinoma
Depolarize the
transmembrane
potential/lysossomal pathway
Ghavami et al., 2008
Buforin IIb Bufo bufo
gargarizans
Frog Leukemia, breast cancer,
non-small cell lung cancer, CNS
cancer, melanoma, renal, ovarian,
prostate and colon cancer
Apoptosis by a
mitochondria-dependent
pathway/caspase-9
activation/cytochrome c
Lee et al., 2008
Cecropins Hyalophora
cecropia
Insect and
mammals
Leukemia, bladder Carpet
mechanism/Membrane
disruption
Steiner et al., 1981; Chen
et al., 1997; Papo and
Shai, 2005; Lehmann
et al., 2006; Suttmann
et al., 2008; Xu et al.,
2008
Cherimolacyclo
peptide C
Annona cherimola Plant Human KB carcinoma NR Wele et al., 2004
Citropin 1.1 Litoria citropa Frog Leukemia, lung, colon, CNS,
melanoma,ovarian, renal,
prostate, breast
Carpet mechanism Doyle et al., 2003
Cn-AMP1 Cocos nucifera Plant Colorectal adenocarcinoma NR Silva et al., 2012
Coibamide A Leptolyngbya sp. Cyanobacteria Breast, CNS, colon, melanoma,
leukemia, ovarian
Cell cycle arrest Medina et al., 2008
CPAP Chlorella
pyrenoidosa
Algae Human liver cancer Condensation/ fragmentation
of nuclear chromatin
Wang and Zhang, 2013
Cr-ACP1 and
Cr-AcACP1
Cycas revoluta Plant Human epidermoid cancer, colon
carcinoma
Cell cycle arrest Mandal et al., 2012
(Continued)
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Table 1 | Continued
Peptides Source Group Application Mechanism of action References
CS5931 Ciona savignyi Tunicate Human colorectal carcinoma Mitochondrial pathway of
apoptosis
Cheng et al., 2012
Cyclotide Clitoria ternatea Plant Lung cancer NR Sen et al., 2013
Cycloxazoline Lissoclinum
bistratum
Ascidian MRC5CVl fibroblasts, T24
bladder carcinoma, leukemia
Cell cycle arrest/inhibition of
cytokinesis
Hambley et al., 1992;
Watters et al., 1994
Dianthins E Dianthus
superbus
Plant Liver hepatocellular cells NR Hsieh et al., 2004
Didemnin Trididemnun
solidum
Ascidian Leukemia, melanoma Protein synthesis
inhibition/apoptosis
Rinehart et al., 1983
Dolastatin 10 Symploca sp.,
Dolabella
auricularia
Cyanobacteria,
mollusk
Murine leukemia cells, lung
cancer
Bcl-2
phosphorylation/Caspase-3
protein activation
Bai et al., 1990;
Kalemkerian et al., 1999
Gaegurins Rana rugosa Frog Kidney, lung, colon, breast,
stomach, liver, prostate, skin,
ovary
Pore formation by
carpet-model
Won et al., 2006
Geodiamolide H Geodia
corticostylifera
Sponge Breast cancer Altering the actin
cytoskeleton
Freitas et al., 2008
Glidobactins A,
B and C
Polyangium
brachysporum sp.
Bacterium Melanoma, leukemia, colon
carcinoma
NR Oka et al., 1988
Homophymines Homophymia sp. Sponge Pancreatic cancer, human
erythromyeloblastoid leukemia,
breast, liver hepatocellular,
human KB carcinoma, human
colon adenocarcinoma, human
ovarian, human prostate,
glioblastoma, lung epithelial cells
NR Zampella et al., 2009
Human
alpha-defensin-1
Homo sapiens Human Human lung adenocarcinoma Apoptosis by cytochrome c
from mitochondria
(mitochondrial pathway)
Xu et al., 2008
Human
neutrophil
Peptides (HNP-1:
β-defensin)
Homo sapiens Human Leukemia and solid tumor Induce membrane proteolysis McKeown et al., 2006
Jamaicamide A Lyngbya
majuscula
Cyanobacterium Human lung, neuroblastoma cell NR Edwards et al., 2004
Jaspamides Jaspis splendens Sponge Lymphoma Caspase-3
activation/decreasing in Bcl-2
protein expression
Ebada et al., 2009;
Ghosh et al., 2010
Kahalalide F (KF) Elysia rufescens Mollusk Colon, breast, non-small cell
lung, prostate carcinoma,
melanoma, hepatocellular
carcinoma
Inhibit expression of genes
involved in DNA
replication/modifies lysosome
membrane/apoptosis inducer
Hamann et al., 1996;
Gracia et al., 2006; Singh
et al., 2008
Keenamide A Pleurobranchus
forskalii
Mollusk Leukemia, human lung
adenocarcinoma, human colon
adenocarcinoma
NR Wesson and Hamann,
1996
(Continued)
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Table 1 | Continued
Peptides Source Group Application Mechanism of action References
Lactoferricin B Bos taurus Mammal Human leukemia, fibrosarcoma,
carcinoma, neuroblastoma
Mitochondria pathway of
apoptosis/cytochrome c
release/activation of the
caspase cascade
Mader et al., 2005;
Eliassen et al., 2006
LL-37 Homo sapiens Human Ovarian cancer Pore formation by
carpet-model
Chuang et al., 2009
Longicalycinin A Dianthus
superbus
Plant Human liver carcinoma NR Hsieh et al., 2005
Lunasin Soybean and
other seeds
Plant Breast cancer NR Hsieh et al., 2010
Lyngbyabellins Lyngbya
majuscula
Cyanobacterium KB carcinoma NR Williams et al., 2003
Magainins Xenopus laevis Frog Hematopoietic tumor,
melanoma, ovarian cancer,
bladder cancer, human cervical
carcinoma
Mitochondria pathway of
apoptosis/Pore formation by
toroidal model/cytochrome c
release/activation of the
caspase cascade/Carpet
mechanism
Zasloff, 1987; Cruciani
et al., 1991; Jacob and
Zasloff, 1994; Takeshima
et al., 2003; Lehmann
et al., 2006
Malevamide D Symploca
hydnoides
Cyanobacterium Leukemia, lung cancer, human
colon carcinoma
NR Horgen et al., 2002
Melittin Apis mellifera Insect Human hepatocellular carcinoma Influx of Ca2+/carpet
mechanism/toroidal pore
Tosteson et al., 1985;
Wang et al., 2009a
Mere15 Meretrix meretrix Bivalve Human lung adenocarcinoma Induce release of cytochrome
c/cleavage of caspases/poly
ADP-ribose polymerase
Wang et al., 2012
Microcolin A Lyngbya
majuscule
Cyanobacterium Breast carcinoma Induction of apoptosis Zhang and Longley, 1999
Mollamide Didemnum molle Ascidian Leukemia, human lung
carcinoma, human colon
carcinoma
NR Carroll et al., 1994
Pardaxinis Pardachirus
marmoratus
Fish Human sarcoma Elevation of caspase
activities, disruption of the
mitochondrial membrane
Huang et al., 2011
Phakellistatin 13 Phakellia fusca Sponge Human hepatoma NR Li et al., 2003
RA-XVII Rubiaceous
plants and Aster
tataricus
Plant Leukemia Activation of caspase activity Hitotsuyanagi et al., 2004
Sansalvamide A Fusarium ssp. Fungi Pancreatic, colon, breast, and
prostate sarcoma, melanoma
Cell cycle arrest Vasko et al., 2010
Scopularide A
and B
Scopulariopsis
brevicaulis and
Tethya Aurantium
Marine fungi,
sponge
Pancreatic tumor, colon tumor NR Yu et al., 2008
StAP1 and
StAP3
Solanum
tuberosum
Plant Leukemia Induces apoptosis Mendieta et al., 2010
(Continued)
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Table 1 | Continued
Peptides Source Group Application Mechanism of action References
Symplostatin 1 Symploca sp. Cyanobacterium Breast, colon tumor Disrupts microtubules/mitotic
arrest/induces apoptosis
Mooberry et al., 2003
Tachyplesin I Tachypleus
tridentatus
Japanese
horseshoe crab
Human hepatocellular
carcinoma, prostate carcinoma
Non-cytolytic mechanism Chen et al., 2005
Tamandarins A
and B
Family
Didemnidae
Ascidian Pancreatic carcinoma, prostatic
cancer, head and neck carcinoma
Protein synthesis inhibition Vervoort et al., 2000
Trapoxins A and
B
Helicoma
Ambiens
Fungi Colorectal cancer NR Itazaki et al., 1990
Virenamides
A–C
Diplosoma virens Ascidian Leukemia, human lung
carcinoma, human colon
carcinoma
Protein synthesis inhibition Carroll et al., 1996
Viscotoxins Viscum
coloratum,
Viscum álbum
Plant Osteoblast-like Sarcoma, Yoshida
sarcoma (rat)
NR Xu and Jin, 1999
Vitilevuamide Didemnum
cuculiferum
(Ascidians)
Ascidian Colon tumor, lung cancer,
melanoma, kidney cancer
Tubulin polymerization/cell
cycle arrest
Edler et al., 2002
NR, Not reported. KB, nasophryngeal cancer; CNS, central nervous system.
Cationic antitumor peptides have been suggested as promising
agents for antitumor therapy due to their numerous advan-
tages over other chemical agents such as their low molecular
masses, relatively simple structures, greater specific cytotoxicity
to tumor cells over healthy cells, fewer adverse reactions, ease of
absorption, a variety of routes of administration and low risk
for inducing multi-drug resistance (Alberts et al., 1980; Mader
and Hoskin, 2006; Hoskin and Ramamoorthy, 2008; Schweizer,
2009; Riedl et al., 2011; Liu et al., 2013). They can also function
in combination with conventional therapies and other potential
anticancer molecules, usually improving the results of therapy
(Chuang et al., 2009; Wang et al., 2009a). The intrinsic rela-
tionship between their chemical structure, i.e., their cationic and
hydrophobic features, and their high specificity to tumor cells
is likely to be the key role for their cytotoxicity. These charac-
teristics allow the cationic AMPs to bind to and invade cancer
cells, quickly disrupting membranes and leading to the outflow
of intracellular contents and consequent cell death (Yeaman and
Yount, 2003; Leuschner and Hansel, 2004; Jenssen et al., 2006).
This happens due to the negatively-charged tumor cell mem-
brane [derived from a greater than normal expression of anionic
molecules such as sialic acid-rich glycoproteins, phosphatidylser-
ine (PS) or heparan sulfate], which present essential differences
with the neutrally-charged healthy cell membranes. Therefore,
these chemical differences aid the electrostatic interaction of the
positively-charged peptide and the negatively-charged tumor cell
membranes (Dobrzynska et al., 2005; Hoskin and Ramamoorthy,
2008). The membranolytic mechanism was first discovered in a
study of magainin and its synthetic analogs against hematopoi-
etic and solid tumors (Cruciani et al., 1991). Cationic antitumor
peptides might also induce disruption of intracellular targets by
so-called non-membranolytic mechanisms. For instance, there
are reports of antitumor peptides that cause necrosis by triggering
intracellular apoptotic pathways (e.g., by inactivating mitochon-
dria; activating caspase cascade) (Mader et al., 2005; Chen et al.,
2012; Paredes-Gamero et al., 2012). Cationic antitumor peptides
can also impair the activity of proteins of the signal transduc-
tion pathways involved in oncogene activities (Sharma, 1992).
Both membranolytic and non-membranolytic mechanisms are
discussed in this review and are represented in Figure 1.
Cationic peptides that kill cancer cells are arranged into two
groups: (1) AMPs which are effective against bacteria and cancer
cells but not against normal mammalian cells such as cecropins
from insects and magainins from amphibians and (2) AMPs
which are cytotoxic for bacteria, cancer cells, and normal mam-
malian cells such as melittin, tachyplesin II, human neutrophil
defensins, and insect defensins (Papo and Shai, 2005; Hoskin
and Ramamoorthy, 2008; Schweizer, 2009). It is believed that
the difference between both groups relay mainly on the differ-
ence of the membrane of tumorous and normal cells (Hoskin
and Ramamoorthy, 2008), therefore it would be essential to
detailed understand these important changes at the molecular
level. To date, it is here understood that besides the differ-
ence on the electrostatic charge between tumorous and normal
cells cited above, the membrane fluidity may also interfere on
the susceptibility of the peptide to disrupt the cells (Hoskin
and Ramamoorthy, 2008). The fluidity of cancer cells is greater
than that of mammalian normal cells (Sok et al., 1999) which
may facilitate membrane destabilization favoring the binding
of cationic antitumor peptides, and the amount of cholesterol,
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FIGURE 1 | Mechanisms of action of cationic antitumor peptides. (1)
Modification of the lysosome membrane leading to an acidification of the
intracellular environment and cell death. (2) Amplification of the
proteasome activity. (3) Induction of mitochondrial pathway of apoptosis
by either the cytochrome c release into the cytoplasm or activation of
the caspase cascade. (4) Pore formation by the carpet model. (5)
Increase of the influx of Ca2+. (6) Formation of pore by either the
toroidal or the barrel-stave models. (7) Activation of an immune
modulatory pathway by induction of NK and IFN. (8) Inhibition of genes
involved in DNA replication. (9) Arrest of cell cycle G0, G1, or S phases.
Lfcin, lactoferrcin; BMAP, bovine myeloid antimicrobial peptide; Cr-AMP,
Chlorella pyrenoidosa antitumor polypeptide.
the major component of eukaryotic cell membranes (Simons
and Ikonen, 2000), alters the membrane fluidity, therefore pro-
tecting eukaryotic cells from cytolytic effects of antitumor pep-
tides. For instance, membrane-insertion of the antitumor peptide
cecropin is shown to reduced when synthetic lipid vesicles and
Gram-negative bacteria have their cholesterol amount enhanced
(Silvestro et al., 1999). Furthermore, the surface area of the mem-
brane of tumorous cells, where the number of microvilli is higher
than on non-tumorous cells (Chaudhary and Munshi, 1995),
may also allow an increased number of peptides to bind to the
membrane (Chan et al., 1998a,b).
In the following sections, cationic antitumor peptides from
both groups which are derived from many sources includ-
ing plants, vertebrates, and invertebrates will be presented (see
Table 1).
CATIONIC ANTITUMOR PEPTIDES ISOLATED FROM PLANTS
High quantities of natural compounds andmolecules from plants
have been intensely studied for the treatment of a diverse number
of diseases including cancer. Reviewed here is a specific class of
cyclic peptides originally found only in plants as well as non-cyclic
peptides with antitumor properties.
Clitoria ternatea is a rich source of a specific class of pep-
tides named cyclotides, composed of a cyclic backbone combined
with a conserved six cystine knot (Craik and Malik, 2013). A
study carried out by Sen et al. (2013) has isolated five cyclotides
named CT2, CT4, CT7, CT10, and CT12 (with an addition or
removal of a net charge from −1 to +2) from this plant species.
They showed significant cytotoxicity against human lung can-
cer cells (A549) and demonstrated a reduction of 2- to 4-fold
of the IC50 (half maximal inhibitory concentration) value of
cyclotides when compared to a mitotic inhibitor used in can-
cer chemotherapy. Moreover, these peptides were less cytotoxic
against A549/paclitaxel (a sub-linage of A594) than only A549,
which demonstrates a possible use of chemo-sensitization for
treating cancer (Sen et al., 2013).
Along with cyclic peptides, many active non-cyclic antitu-
mor peptides have also been isolated from different plants. For
instance, the promiscuous peptide Cn-AMP1, isolated and puri-
fied from coconut water (Cocos nucifera), was tested against
CACO-2- human epithelial colorectal adenocarcinoma cells and
showed a 13% reduction of cell viability (Silva et al., 2012).
Additionally, the peptide lunasin, isolated from soybeans and
other seeds, was capable of suppressing in vitro and in vivo
chemical carcinogen-induced tumorigenesis (Hsieh et al., 2010).
StAP1 and StAP3, isolated from the potato Solanum tubero-
sum, were shown to induce apoptosis in Jurkat T leukemia
cells (Mendieta et al., 2010; Guevara et al., 2011). Other
examples are the peptides Cr-ACP, isolated from Cycas rev-
oluta, and its acetylated-modified Cr-AcACP1, both repres-
sors of cell proliferation of human epidermoid cancer (Hep2),
and colon carcinoma through the induction of cell cycle
arrest at the G0–G1 phase of Hep2 cells (Mandal et al.,
2012).
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Among chlorophyllous organisms, few studies have been
developed. One example is the polypeptide Chlorella pyrenoi-
dosa antitumor polypeptide (CPAP) isolated from the unicellu-
lar green algae Chlorella pyrenoidosa. It has shown the highest
inhibitory activity on human liver HepG2 cancer cells (49%).
CPAP induces apoptosis and necrotic death of HepG2 cells via
membrane shrinkage, condensation and fragmentation of nuclear
chromatin as well as formation of black apoptotic bodies (Wang
and Zhang, 2013).
CATIONIC ANTITUMOR PEPTIDES ISOLATED FROM INVERTEBRATES
Bioactive peptides isolated from insects present many different
activities and have strong potential as therapeutic agents (Table 1)
(Chernysh et al., 2002). Cecropins, alloferons, and melittins are
examples of AMPs isolated from insects which function as antitu-
mor molecules with applications for various kinds of tumor cells
(Figure 1). The AMP cecropin was first isolated from the giant
silk moth Hyalophora cecropia (Steiner et al., 1981). Cecropins
shares their potential antitumor activity with structural analogs
from other families of AMPs such as magainins and defensins
(Papo and Shai, 2005; Lehmann et al., 2006). It has been shown
that two cecropin B analogs, cecropin B1 (CB1) which possesses
two amphipathic helices, and cecropin B3 (CB3) which has two
hydrophobic helices, exhibit strong cytotoxic activity against a
number of human leukemia cell lines and do not lyse normal
fibroblasts or erythrocytes (Srisailam et al., 2001). Both analogs
exhibit drastically different mechanisms of actions on anionic
lipid vesicles and show the importance of the structure and
sequence of a cationic antitumor peptide and its potency toward
different cancer cells (Srisailam et al., 2001). It has been claimed
that the discontinuous helical segments in the structure of CB3
do not favor helix—helix interactions which are crucial for pore
formation; these mechanisms are likely to be adopted by CB1
where the continuous helical conformation interacts with cell-
surface structures such as microvilli in cancer cells. In a different
study, CB1 was a more powerful cytolytic agent than cecropin B
against HL-60 human promyelocytic leukemia cells (Chan et al.,
1998a,b). Cecropin A and B have been shown to reduce the viabil-
ity of bladder cancer cells (Suttmann et al., 2008) and to directly
induce tumor cell lysis via cell membrane disruption, which stim-
ulates cytolysis/necrosis. Furthermore, it was shown that these
peptides are capable of imposing the disruption of mitochondrial
membranes, consequently leading to the activation of apoptosis
pathways (Suttmann et al., 2008).
Another important AMP isolated from insects is alloferon:
a tridecapeptide isolated from the bacteria-challenged larvae of
the blow fly Calliphora vicina. Synthetic alloferon I has been
shown to act on tumor growth control in two different ways. It
stimulates natural killer (NK) lymphocytes and interferon (IFN)
in vitro by using mouse spleen lymphocytes and human blood
mononuclear cells. The peptide was administrated in picomolar
concentrations where its potential to stimulate natural cyto-
toxicity in these models was confirmed. Alloferon also induces
IFN synthesis in vivo which was demonstrated using animal
and human models, and consequently enhancing its antitumor
activity (Figure 1). Based on these results, the researchers have
suggested an interaction of alloferon anticancer activity with
its immunomodulatory properties. The interferonogenic activ-
ity was more evident in vitro using human cells than in vivo,
while in comparison to mouse cells the opposite result was
observed. The NK-IFN network is well-documented and demon-
strates the potential immune modulatory properties of this AMP.
Furthermore, it has been recently shown that the combination
of chemotherapy and alloferon I, referred to as pulse immune
chemotherapy, demonstrated significant advantages compared to
each treatment applied separately (Chernysh et al., 2002, 2012).
Also from the group of insects, the AMPmelittin, isolated from
Apis mellifera, is also an active molecule against antitumor cells.
It is cytotoxic against human hepatocellular carcinoma (Tosteson
et al., 1985; Wang et al., 2009a). Studies indicate that melittin
damages cell membranes either via the barrel-stave mechanism,
i.e., it acts under its membranolytic properties (Sui et al., 1994),
or via its non-membranolytic properties through a mechanism
that engages the hyperactivation of phospholipase A2 and the
influx of Ca2+, resulting in the destruction of the transformed
cells (Figure 1) (Sharma, 1992, 1993).
Another antiviral AMP within the group of invertebrates is the
peptide AGAP isolated from the scorpion Buthus martensii. It has
been reported to possess both analgesic and antitumor activities.
Recently, a heterologous expression system has been constructed
using small ubiquitin-related modifier-AGAP (SUMO-AGAP)
which is a product of recombinant AGAP (rAGAP) linked with a
hexa-histidine tag from Escherichia coli. This recombinant system
showed considerable inhibition of lymphoma and glioma propa-
gation (Gu et al., 2013). Using SW480 human colon cancer cells,
it was proposed that rAGAP induces cell cycle arrest in the G0/G1
phase, attended by the decrease in the S phase without significant
change in the G2/M phase (Gu et al., 2013).
Other sources of cationic peptides isolated from invertebrates
are found in the marine ecosystem. The biodiversity of this envi-
ronment has been shown to be a rich source of biologically active
molecules and has been considered an unlimited resource of
new antitumor agents (Zheng et al., 2011; Malaker and Ahmad,
2013). Several AMPs with antitumor activity have been isolated
frommarine invertebrates such as cyclic depsipeptide didemnins.
Isolated from the ascidian of the genusTrididemnum, it has shown
antitumor activity against L1210 leukemia cells in vitro and P388
leukemia and B16 in vivo (Rinehart et al., 1983). The antitumor
role of the peptide kahalaide F from Elysia rufescens, a marine
gastropod mollusk, has also been reported. It has shown sig-
nificant in vitro and in vivo activity against non-small cell lung
cancer, colon and human breast tumor cell lines, melanoma,
androgen-independent prostate cancer and hepatocellular carci-
noma (Martin-Algarra et al., 2009; Malaker and Ahmad, 2013).
This peptide acts on the liposome membrane of tumor cells and
modifies its basal function (Figure 1) (Hamann et al., 1996; Singh
et al., 2008). Moreover, it modifies the role of the lysosomal
membrane, leading to intracellular acidification and cell death,
a characteristic that discriminates it from all other known anti-
tumor agents (Gracia et al., 2006). This peptide also appears to
inhibit the expression of certain specific genes that are involved in
DNA replication and cell proliferation, thereby inhibiting tumor
spreading and growth. Recently another marine AMP isolated
from the bivalve Meretrix meretrix, named mere15, has shown to
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significantly inhibit the growth of human lung adenocarcinoma
A549 xenograft in nude mice (Wang et al., 2012).
CATIONIC ANTITUMOR PEPTIDES ISOLATED FROM VERTEBRATES
Many peptides have been discovered from a variety of verte-
brates that are responsible for improving the innate immune
response (Table 1) They have been found at relatively low con-
centrations in the normal tissues of mammals and are usually
present within the granules of neutrophils, in mucosal or skin
secretions from epithelial cells, and as the degradation products of
proteins (Boman, 1995; Hancock, 2001). Among the mammalian
organisms, bovines have been a promising source of molecules
which show a broad range of physiological activities, including
immune function enhancement and defense against pathogenic
bacteria and viruses. Among these molecules, three AMPs named
BMAP-27, BMAP-28 and lactoferricin have been reported as
active antitumor peptides. The bovine myeloid AMPs BMAP-27
and BMAP-28 (27 and 28 amino acid residues, respectively) have
shown cytotoxic activity against neoplastic cells. These peptides,
when tested against fresh tumor leukocytes from patients affected
by myeloid or lymphoid leukemia, have shown to increase mem-
brane permeabilization and the influx of Ca2+, followed by DNA
fragmentation, which is characteristic of programmed cell death
(Figure 1) (Risso et al., 1998).
The cytotoxic activity of bovine lactoferricin (LfcinB) has been
demonstrated in vitro with different rat and human cancer cell
lines including leukemia, fibrosarcoma, various carcinoma, and
neuroblastoma cells, and did not influence the viability of nor-
mal fibroblasts, lymphocytes, epithelial cells, endothelial cells, or
erythrocytes (Yoo et al., 1997; Mader et al., 2005; Eliassen et al.,
2006). It has been proposed that Lfcin targets tumor cells by the
changes that occur in their cell membranes, such as the expo-
sure of negatively-charged head-groups derived from the loss of
phospholipid asymmetry in diseased cells (Gifford et al., 2005;
Pepe et al., 2013). The activities against fibrosarcoma and neu-
roblastoma rat cells and human T-leukemia cells can be described
by a mechanism that induces the formation of transmembrane
pores allowing the peptide to enter the cytoplasmic compartment
of the cancer cell, co-localize with negatively-charged mitochon-
dria and consequently depolarize them, resulting in cytochrome
C release or activation of the caspase cascade, thereby leading to
cell death via apoptosis (Figure 1) (Mader et al., 2005; Pepe et al.,
2013). Moreover, it may interfere with the interaction between
growth factors and their receptors on the surface of endothe-
lial cells, resulting in decreased endothelial cell proliferation and
diminished angiogenesis (Mader et al., 2006). As reviewed by
Gifford and colleagues, other mechanisms have been proposed.
In brief, upon binding to the tumor cells, Lfcin is thought to trig-
ger a Ca2+/Mg2+ endonuclease and oxidant-dependent apoptotic
pathway. Although the structural parameters that describe the
antitumor effects of Lfcin are very similar to those that describe its
antibacterial activity, a higher net positive charge (+7 when com-
pared to +4 for antibacterial activity) is required for antitumor
activity to promote a strong electrostatic interaction between the
peptide and the membrane (Figure 1) (Gifford et al., 2005).
Among the human-derived mammalian AMPs, the amphi-
pathic α-helical LL-37 has been extensively studied as an
antibacterial peptide. Besides its strong activity against bacteria,
it has also shown to be cytotoxic against ovarian cancer (Chuang
et al., 2009) and is toxic to eukaryotic cells at a slightly higher
concentration (25–30mM) (Hoskin and Ramamoorthy, 2008).
Regarding its mechanism of action, it is known that upon binding
to membranes it changes the head group conformation of phos-
pholipids, induces positive curvature strain on lipid bilayers, and
significantly disorders the hydrophobic core of the membranes,
exhibiting the carpet-like rather than the channel/pore-forming
mechanism of cytotoxicity (Figure 1) (Henzler Wildman et al.,
2003; Henzler-Wildman et al., 2004; Hoskin and Ramamoorthy,
2008).
Within the class of amphibians, the order Anura has been
shown to be a rich source of AMPs. Their skin has diverse phys-
iological activities and forms an essential part of their defense
systems. In response to a multiplicity of stimuli, AMPs can be
secreted from specific glands onto the dorsal surface and into
the gut of the amphibian (Bevins and Zasloff, 1990; Barra and
Simmaco, 1995; Doyle et al., 2003).
In comparison to synthetic magainins A, B, and G, the nat-
ural peptide magainin-2, isolated from the skin of the frog
Xenopus laevis, is the most efficient peptide and causes fast lysis of
hematopoietic and solid tumor cell lines including many human
bladder cell lines (Cruciani et al., 1991; Jacob and Zasloff, 1994).
Magainin-2 has been shown to enter the cell membrane of HeLa
human cervical carcinoma cells by binding numerous magainin
helices forming a toroidal pore in the lipid molecules of artificial
membranes (Matsuzaki et al., 1996). It has also been reported that
pore formation is followed by a dispersing membrane potential
and leakage of intracellular molecules, consequently leading to
cell death (Takeshima et al., 2003). Magainin are shown to access
the cytosolic compartment of cancer cells and cause the mito-
chondrial pathway of apoptosis via a mechanism that involves
cytochrome c release into cytoplasm and an amplified proteasome
activity, confirming its apoptotic effect (all these mechanisms
are shown in Figure 1) (Westerhoff et al., 1989; Cruz-Chamorro
et al., 2006).
Another example of potential antitumor AMPs belonging to
the order Anura are gaegurin and buforin. The peptide gaegurin
was purified from the skin of the Korean frog Rana rugosa. It is
a potent mediator of cytolysis using either the carpet or barrel-
stave mechanism (Park et al., 1994; Hoskin and Ramamoorthy,
2008) and is also reported to follow the mitochondria pathway
of apoptosis as described above for the magainin mechanism of
action (Li et al., 2000; Mai et al., 2001).
Buforin II, a linear α-helical peptide similar to cecropins and
magainins, was isolated from the stomach of the Bufo bufo gar-
garizans and is known to penetrate cell membranes through non-
permeabilizing pore-like structures which allow its translocation
into the cytoplasm without cell lysis, and consequently inhibits
intracellular functions (Park et al., 1998). It has been shown that
the cytotoxic activity of buforin II is low when compared with cit-
ropin 1.1, pexiganan MSI-78 and protegrin 1, and that it does not
permanently disrupt the cell membrane like other molecules, i.e.,
its antitumor activity corroborates with the mechanism described
above (Koszalka et al., 2011). A synthetic analog of buforin II
named buforin IIb has shown greater cytolytic activity against
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cancer cells (leukemia, breast cancer, non-small cell lung can-
cer, CNS cancer, melanoma, renal, ovarian, prostate, and colon
cancer) than buforin II (Lee et al., 2008).
From the group of marine vertebrates, the cationic peptide
pardaxin isolated from the small fish Pardachirus marmoratus has
been shown to be a potential active antitumor peptide against
human sarcoma (Huang et al., 2011). It has been reported that
this peptide disrupts the membrane via the barrel-stave mech-
anism (Hallock et al., 2002), and changes its transmembrane
orientation depending on membrane composition (Hoskin and
Ramamoorthy, 2008).
CATIONIC ANTIVIRUS PEPTIDES
The success of viruses in evolution has been assured by four
general attributes: genetic variation, variety in means of trans-
mission, efficient replication within host cells, and the abil-
ity to persist in the host (Wagner et al., 1999). Due to these
attributes, the control of viral diseases has not been an easy
task. Despite the existence of antiviral drugs, there is a need to
explore novel antiviral compounds in order to control emerg-
ing viral pathogens. In this perspective, AMPs are an alternative
in drug design. Several cationic antiviral peptides from vari-
ous sources have been isolated since the 1980s (Table 2) and
they have shown strong potential for novel therapeutic drugs
against many viral infections. Due to the promiscuity of these
peptides, it is possible to verify a broad spectrum of antiviral
activities within the same peptide. Moreover, this promiscuous
activity can be extended to simultaneous cytotoxic activity against
tumor cells (Figure 2). The first study reporting an antiviral
role of a cationic peptide was published in 1986, in which the
activity of α-defensin was described as inhibiting a number of
viruses including herpes simplex virus types 1 and 2 (HSV),
cytomegalovirus (CMV) as well as inhibiting the vesicular stom-
atitis virus with human neutrophil peptide 1 (HNP1) in vitro
(Daher et al., 1986; Findlay et al., 2013). Since then, many reports
have shown the antiviral activity of cationic host-defense peptides
such as α-, β-, and θ-defensins, and the use of effective antivi-
ral therapy with cathelicidins, as previously reviewed (Findlay
et al., 2013). It is very promising that in the last years many
new antiviral peptides have been either identified or synthesized
in order to aid the development of new therapeutic antivirus
therapies.
CATIONIC ANTIVIRAL PEPTIDES DRUGS APPLIED TO HUMAN HEALTH
Cationic antiviral peptides have been isolated from various
sources and present broad antiviral activities against several
viruses with different antiviral mechanisms of action (Table 2).
They can either inhibit viral attachment by binding to viral targets
on the host cell surface, or target viral proteins, therefore block-
ing viral fusion and entry into the host cell. Another mechanism
of action is intracellularly driven where spreading of the virus
is inhibited through the suppression of viral gene expression,
inhibition of translation or by immune modulatory activities
(Figure 3).
CATIONIC ANTIVIRAL PEPTIDES ISOLATED FROM INVERTEBRATES
AMPs isolated from the group of invertebrates which present
strong antiviral activity against maladies that affect human health
are well-represented by peptides such as melittin, cecropin, and
alloferon. Described above as an antitumor peptide, melittin has
also been reported to have inhibitory activity against enveloped
viruses such as HIV-1, HSV-2, and the Junin virus (JV), an
arenavirus, including this peptide under the concept of promis-
cuity (Figure 2). A proposed mechanism of action has suggested
that melittin suppresses cell fusion mediated by HSV-1 syncytial
mutants probably by interfering with the activity of the Na+ K+
ATPase, a cellular enzyme involved in the membrane fusion pro-
cess (Albiol Matanic and Castilla, 2004). Analysis of the effect of
melittin on the production of HIV-1 transcripts was assayed in
acutely infected T-cells cultured with various concentrations of
melittin. Levels of all HIV-1 transcript classes were suppressed
(reduction of ∼30% when compared with cells without melittin)
in a dose-dependent manner (Wachinger et al., 1998). Another
mechanism whereby melittin interferes with viral gene expres-
sion has been proposed and involves intracellular immunization
against HIV (Figure 3). Melittin interfere in the process of cellu-
lar signal transduction, such as the activation of phospholipase
A2 for instance, and the decrease in activities of calmodulin and
protein kinase C (Sharma, 1993; Fisher et al., 1994; Gravitt et al.,
1994). These properties may therefore change the balance and
activities of cellular stimulators of HIV transcription (as NFkB,
AP-1 and NFAT) or induce inhibitory factors (interferon-induced
cellular inhibitor) (Wachinger et al., 1998).
The peptides alloferon 1 and 2 have shown activity against the
influenza virus, through the samemechanism described above for
its role as an antitumor peptide, by induction of immune modu-
latory activities. Both activities against tumor and viral infections
emphasize the mechanisms of cell-mediated natural cytotoxicity
and IFN synthesis (Figure 3). Therefore, these peptides seem to be
potential candidates as biopharmaceutical compounds contain-
ing the capability of improving important effector mechanisms
of the innate immune response (Chernysh et al., 2002).
Another example of invertebrate peptides with antivirus activ-
ity against human virus-related diseases is the synthetic peptide
T22 ([Tyr5, 12, Lys7]-polyphemusin II), which is associated with
the promiscuous peptide tachyplesin (Figure 2) and the pep-
tide polyphemusin, which are abundant in the hemocytes of the
horseshoe crab Tachypleus tridentatus and Limulus polyphemus,
respectively. It has shown potent antiviral activity against HIV-
1 and HIV-2 in vitro. The inhibitory activity of this peptide is
related to its specific binding to a chemokine receptor CXCR4,
which serves as a co-receptor for the entry of HIV-1 into T cells
(Figure 3) (Nakashima et al., 1992; Tamamura et al., 1998).
CATIONIC ANTIVIRAL PEPTIDES ISOLATED FROM VERTEBRATES
There are several AMPs derived from mammalian sources which
have demonstrated strong activity against many viruses that com-
promise human health (Table 2). In this group are included
defensins, Lfcin and LL-37 (Figure 2). Defensins are potent can-
didates for the development of antiviral drugs. They are peptides
with conserved structures, usually with α-helix and antiparallel
β-sheets stabilized by disulfide bonds (Terras et al., 1992; Bastian
and Schafer, 2001; Franco et al., 2006), and belong to three
subfamilies, designated α, β, and θ defensins. The HNP-1 is an α-
defensin that have been widely tested for its antiviral activity. This
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Table 2 | Cationic antiviral peptides from different sources, their application, and their mechanisms of action.
Peptide Source (s) Group Application Mechanism of action References
HUMAN HEALTH
Alloferon 1
Alloferon 2
Calliphora vicina Insect IAV Immunomodulatory
activity
Chernysh et al., 2002
Brevinin-1 Rana brevipoda Frog HSV Viral inactivation Yasin et al., 2000
Caerin 1.1
Caerin 1.9 Maculatin
– Amphibian Skin HIV Disrupts the integrity of
the virion membrane
Vancompernolle et al., 2005
CAP37 Homo sapiens Human
leococytes
HSV-1
AdV
Disrupts the envelope
and/or capsid
Gordon et al., 2009
Cecropin Hyalophora cecropia Insect JV
HSV
HIV
Suppresses viral protein
synthesis Cellular target
Suppresses viral gene
expression
Wachinger et al., 1998; Albiol
Matanic and Castilla, 2004
Circulin A Chassalia parvifolia Plant HIV Daly et al., 1999
Defensin Homo sapiens Human HSV
IAV
HCMV
VSV
HIV
AdV
Interacts with
glycosaminoglycans
Inactivates viral particle
Cellular target
Unknown
Daher et al., 1986; Nakashima
et al., 1993; Gropp et al., 1999;
Yasin et al., 2000; Bastian and
Schafer, 2001; Sinha et al., 2003
Dermaseptin Genus Phyllomedusa Frog HIV
HSV
Disruptis viral membrane Belaid et al., 2002
Didemnins A
Didemnins B
Genus Trididemnum Tunicate HSV
Parainfluenza
Dengue
virus
Inhibits RNA and DNA viral
replication
Rinehart et al., 1981; Aneiros and
Garateix, 2004
HNP-1
HNP-3
Homo sapiens Human HSV
AdV
Blocks early steps of viral
replication
Ganz et al., 1985; Bastian and
Schafer, 2001; Hook et al., 2006
Hp1090 Heterometrus petersii Scorpion HCV Disrupts viral membrane
integrity
Yan et al., 2011
Indolicidin Bos taurus Bovine HIV
HSV
Inhibits integrase
Targets viral
glycosaminoglycans
Robinson et al., 1998
Lactoferricin Homo
sapiens
Bos taurus
Human, Bovine HCMV
HIV
HSV
Papilloma
Activity at virus-cell
interface
Blocks heparan sulfate
Andersen et al., 2001; Jenssen
et al., 2004; Mistry et al., 2007
LL-37 Homo sapiens Human HSV
IAV
Viral receptor-based
mechanisms
Yasin et al., 2000; Barlow et al.,
2011
Magainin Xenopus laevis Frog HSV
HIV
Suppresses viral gene
expression
Aboudy et al., 1994; Albiol
Matanic and Castilla, 2004
Mellitin Apis mellifera Insect HSV
JV
Cellular target Wachinger et al., 1998; Yasin
et al., 2000; Albiol Matanic and
Castilla, 2004
Microspinosamide Sidonops
microspinosa
Marine sponge HIV Inhibits cytopathic effect of
HIV-1 infection
Rashid et al., 2001
(Continued)
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Table 2 | Continued
Peptide Source (s) Group Application Mechanism of action References
Pa-MAP Pleuronectes
americanus
Fish HSV Interacs with viral envelope Migliolo et al., 2012
PAP Phytolacca americana Plant HIV
HBV
HSV
Inhibits viral protein
synthesis
Kaur et al., 2011
Polyphemusin Tachypleu tridentatus Horseshoe crab HIV Binds gp120 and CD4 Nakashima et al., 1992;
Tamamura et al., 1996
Protegrin Homo sapiens Human HIV
HSV
Unknown
Viral inactivation
Yasin et al., 2000; Steinstraesser
et al., 2005
Tachyplesin Tachypleus
tridentatus
Horseshoe crab HIV
HSV
VSV
IAV
Virus-cell fusion
Viral inactivation
Viral envelope
Morimoto et al., 1991; Murakami
et al., 1991; Yasin et al., 2000
θ-defensin Homo sapiens Human HIV
HSV
Binds glycosylated gp120
Binds gB and blocks viral
attachment
Cole et al., 2002; Yasin et al.,
2004
ANIMAL HEALTH
Cecropin B
CF17
Hyalophora cecropia Insect
Synthetic
IHNV
VHSV
SHRV
IPNV
Disrupts the viral envelope
Disintegrates the viral
capsids
Chiou et al., 2002
Epinecidin-1
TH 1-5
cSALF
Oreochromis
mossambicus
Penaeus monodon
Fish
Shrimp
NNV Agglutinates NNV virions
into clump
Chia et al., 2010
Pleurocidin MDPle Limanda limanda Fish VHSV Disrupts the viral
membrane via toroidal
pore formation model
Falco et al., 2009
AGRICULTURE
Potide-G Solanum tuberosum L Plant PVYO Unknown Tripathi et al., 2006
PAP Phytolacca americana Plant TMV
CMV
CaMV
Inhibit viral protein
synthesis
Chen et al., 1991
Indolicidin Bos taurus Bovine
neutrophils
TMV Unknown Bhargava et al., 2007
Peptamine Pseudomonas
chlororaphis O6
Bacteria TMV Unknown Park et al., 2012
Analogs of melittin Apis mellifera Synthetic TMV Cellular target Marcos et al., 1995
Adapted from (Jenssen et al., 2006); –Not reported. AdV, adenovirus; CaMV, cauliflower mosaic virus; CMV, cytomegalovirus; HBV, hepatitis B virus; HCMV, human
cytomegalovirus; HCV, hepatitis C virus; HIV, Human immunodeficiency virus; HSV, hermpes simplex virus; IAV, influenza; IHNV, infectious haematopoietic necrosis
virus; IPNV, infectious pancreatic necrosis virus; JV, junin virus; NNV, nervous necrosis virus; PVYO, potato virus YO; SHRV, snakehead rhabdovirus; TMV, tobacco
mosaic virus; VHSV, viral hemorrhagic septicemia; VSV, vesicular stomatitis virus; VSV, vesicular stomatitis virus.
peptide has been reported to deactivate HSV-1 and HSV-2, CMV,
vesicular stomatitis virus, influenza virus and human respiratory
adenovirus type-5 (AdV-5) (Daher et al., 1986; Yasin et al., 2004).
Treatment with this peptide has shown a decrease of adenoviral
infection by more than 95% in 293 cells infected with AdV-5)
(Bastian and Schafer, 2001). θ-defensins are circular octade-
capeptides with two antiparallel β-sheets that are bridged by a
tri-disulfide ladder and connected by two β-turns (Yasin et al.,
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FIGURE 2 | Promiscuous cationic peptides with antitumor and
antiviral activities. Each promiscuous peptide and their various
tumors against which present cytotoxic activity (top) and viruses
against which present antiviral activity (bottom). #PDB from left to
right, 2IGR, 2K6O, 2LSA, 1Z6V, 2MLT, 1WO1. HCMV, human
cytomegalovirus; HIV, Human immunodeficiency virus; HSV, herpes
simplex virus; IAV, influenza; IHNV, infectious hematopoietic necrosis
virus; IPNV, infectious pancreatic necrosis virus; Jv, Junin virus;
SHRV, snakehead rhabdovirus; VHSV, viral hemorrhagic septicemia;
VSV, vesicular stomatitis virus.
2004). This class of peptide has been reported to be miniature
lectins that bind to the protein gp120 of human immunodefi-
ciency virus type 1 (HIV-1) with high affinity, blocking its entry
into the host cell (Figure 3) (Munk et al., 2003).
The promiscuous peptide LfcinB (Figure 2) has shown inhi-
bition against many viruses such as HIV-1, HSV-1, and HSV-2,
human cytomegalovirus (HCMV), respiratory syncytial virus,
hepatitis B and C viruses (HBV and HCV, respectively), aden-
ovirus, and rotavirus (Van Der Strate et al., 2001; Andersen et al.,
2003). The activity of Lfcin has been claimed to be attributed
to the affinity of this peptide for carbohydrates, which are viral
binding sites on the cell membrane, such as heparin sulfate
(HS) and glycosaminoglycans (GAGs), thereby blocking viral
entry (Andersen et al., 2003). The antiviral activity of LfcinB
and LfcinH (human lactoferricin) against HSV has been verified
with the ability of this peptide to interact with HS and block
viral entry. It has been found that the positive net charges of
the peptides are critical for affinity with HS which is due to the
many negatively-charged sulfate groups present in the molecule
(Jenssen et al., 2004). Together with Lfcin, the peptides human
α-defensin, LL-37 and magainin have also been reported to bind
to GAGs in order to perform their respective activities (Figure 3)
(Jenssen et al., 2006). It has also been shown that a stabilized
secondary structure is important for antiviral activity for both
LfcinB and LfcinH (human lactoferricin). The higher potency of
LfcinB against some viruses compared to LfcinH is attributed to
the β-sheet conformation of LfcinB in solution compared with the
α-helical structures of LfcinH (Jenssen et al., 2004).
Lactoferrin (Lf), the protein from which the peptide Lfcin
is derived, shows antiviral activity against a number of viruses
as much as seven times greater than that of Lfcin, proposing
that either the size of the molecule is important or that other
regions of LF contribute to the antiviral activity (Andersen et al.,
2003; Gifford et al., 2005). The positive charge of Lf was found
to be important for antiviral activity against human HCMV
(Valenti and Antonini, 2005). When negatively-charged groups
were added to Lf by succinylation, the antiviral potency was
mostly decreased, whereas the addition of positive charges to
Lf through amination of the protein resulted in increased anti-
HCMV activity (Harmsen et al., 1995). On the other hand,
when tested against HIV-1, a 4-fold stronger antiviral effect of
Lf was observed when negatively-charged groups were added
(Harmsen et al., 1995). The proposed mechanism of action for
anti-HIV activity was that Lf and the charged-modified protein
bind strongly to the V3 loop of the gp120 envelope protein,
increasing the net negative electric charge of viral particles, and
resulting in inhibition of virus-cell fusion and entry of the virus
into cells (Puddu et al., 1998) Another report of direct interaction
of viral proteins with Lf has been observed in HCV. Inhibition of
virus-cell adsorption was verified in human hepatocytes PH5CH8
when bLf was mixed prior to the viral infection in serum con-
taining HCV, and no antiviral activity of bLf was observed after
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FIGURE 3 | Mechanisms of action of cationic antiviral peptides. Cell
surface targets: (1) Interaction of peptides with different glycosaminoglycan
(e.g., HS) present on the cell surface competing with the virus for cellular
binding sites. (2) Blocking of viral entry into the cell by binding the peptide to
viral CXCR4co-receptor required for its entry. (3) Suppression of cell fusion by
interfering with the activity of ATPase protein. Intracellular targets: (4)
Suppression viral gene expression. (5) Inhibition of peptide chain elongation
by inactivating the ribosome. (6) Activation of an immune modulatory
pathway by induction of NK and IFN. Viral protein targets: (7) Binding of
peptides to viral proteins causing inhibition of adsorption/virus-cell fusion.
internalization of HCV in human hepatocytes (Ikeda et al., 1998).
This activity has been reported to be involved in the ability of
hLF and bLF to bind to E1 and E2 proteins of the viral enve-
lope, indicating that neutralization occurs in order to prevent the
adsorption of HCV in the hepatocytes (Yi et al., 1997). During
in vivo experiments, bLF protected the host mice against infec-
tion of the mouse cytomegalovirus (MCMV) when the peptide
was injected prior to the viral infection, but failed to protect the
mice when the injection was performed after MCMV infection
(Shimizu et al., 1996).
Another human-derived peptide which targets enve-
lope/membrane is the promiscuous peptide CAP37, first
isolated from the granule fractions of human PMNs. It has
been shown to have potent activity against viruses (HSV-1
and Adenovirus), bacteria (Pseudomonas aeruginosa, E. coli,
Salmonella typhimurium, Staphylococcus aureus, and Enterococcus
faecalis), and fungi (Candida albicans). Its structure/function
differs from the others peptides here mentioned. It is known
that cystine residues forming intramolecular disulfide bridges
are necessary for the antibacterial function of CAP37 but are not
required for its antiviral activity, which has been suggested to be
involved in the rupture of the envelope and/or capsid (Gordon
et al., 2009).
The promiscuous peptide LL-37 (Figure 2) differs from the
above defensins, Lfcin, and bLf in its mechanism of action.
Instead of targeting cell surface molecules, it inhibits viral spread-
ing by inactivating intracellular targets (Figure 3). LL-37 have
nuclear localization signals and have been related to interact with
DNA, directly influencing viral nucleic acid synthesis (Sandgren
et al., 2004). The same is applied to indolicidin, a peptide iso-
lated from the cytoplasmic granules of bovine neutrophils (Hsu
et al., 2005). However, besides its DNA-binding ability, it has
also shown activity against HIV and HSV through a membrane-
mediated antiviral mechanism (Robinson et al., 1998).
Marine organisms are also included as a source of cationic
antiviral peptides (Table 2). One example is the promiscuous
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peptide Pa-MAP isolated from the fish Pleuronectes americanus,
which beyond having shown broad antimicrobial activity against
bacteria (E. coli and S. aureus), fungi (Candida parapsilosis,
Trichophyton mentagrophytes, and Trichophyton rubrum) and
tumor cells in culture (CACO-2, MCF-7, and HCT-116), also has
activity against viruses (HSV-1 and HSV-2). The antiviral mech-
anism of this peptide has been suggested to involve its interaction
with the viral envelope (Migliolo et al., 2012; Teixeira et al., 2013).
A group of cationic antiviral peptides from vertebrate and
invertebrate sources has been tested by Carriel-Gomes et al.
(2007). This study has shown in vitro evaluation of the cytotox-
icity and antiviral activity of nine AMPs against many human
viruses (Carriel-Gomes et al., 2007). They were PW-2 recombi-
nant, tachyplesin-1 from limulid, gomesin from spider, clavanin
A from tunicate, magainin from frog, synthetic HCTF, penaeidin-
3 and ALF from shrimp, and mytilin A from mussel. These
peptides have different structures, origins and antiviral activi-
ties against HSV-1, AdV-5, and rotavirus SA11 (RV-SA11). All
evaluated peptides were cytotoxic and had antiviral activities
in different degrees. The peptides PW-2, ALF and penaeidin-3
exhibited higher antiviral activity against HSV-1. The peptides
ALF and clavanin A showed significant antiviral activity against
AdV-5 with clavanin A exhibiting a greater inhibition of viral
replication (Carriel-Gomes et al., 2007).
ANTIVIRAL PEPTIDES DRUGS APPLIED TO ANIMAL HEALTH
Several studies have reported the efficiency of AMPs active against
viruses that cause diseases in humans. However, few studies
have demonstrated the potential application of these peptides
in animal health. Here we present studies showing the appli-
cation of antiviral peptides in aquaculture. Viral diseases have
emerged as the most serious infectious problems for the fish
aquacultural industry, and studies have found promising cationic
antivirus peptides being used against several viruses includ-
ing rhabdoviruses such as viral hemorrhagic septicemia virus
(VHSV) and infectious hematopoietic necrosis virus (IHNV),
which are responsible for the greatest losses in aquaculture pro-
duction.
The native cecropine B and its synthetic analog CF17, have
demonstrated activity against major viral fish pathogens such
as infectious hematopoietic necrosis virus (IHNV), viral hemor-
rhagic septicemia virus (VHSV), snakehead rhabdovirus (SHRV)
and infectious pancreatic necrosis virus (IPNV). The mechanism
of action involved in the inhibition of viral replication by pep-
tides is related to the direct disruption of the viral envelop and
the disintegration of the viral capsids (Chiou et al., 2002).
Chia and collaborators reported that both peptides tilapia hep-
cidin 1-5 (TH 1-5) and cyclic shrimp anti-lipopolysaccharide fac-
tor (cSALF) exhibited noticeable antiviral activity in vitro against
nervous necrosis virus (NNV), a virus that has caused mass mor-
tality of numerous marine fish species at their larval stage. The
antiviral mechanism of both peptides was by agglutinating NNV
virions into clump and preventing viral entry into the cells (Chia
et al., 2010). Together with hepcidin 1-5, the peptide hapcidin
1 has also shown antiviral activity in vivo against NNV in the
Japanese rice fish medaka (Oryzias latipes). Pre-treatment, co-
treatment or post-treatment with epinecidin-1 or hepcidin 1-5
has shown to be effective in promoting a significant increase in
medaka survival when infected with NNV (Wang et al., 2010a).
Falco and collaborators (2009) have reviewed the role of
many AMPs as antiviral agents in the fish farm industry. Among
these molecules there are pleurocidin and the HNP1. Pleurocidin
MDPle, isolated from the Mud dab fish (Limanda limanda), has
presented antiviral properties against VHSV. It is likely that it dis-
rupts the viral membrane under the same mechanisms adopted
for its antibacterial activity (Falco et al., 2009). The HNP1 is a
defensin that has demonstrated antiviral effects against the same
virus as MDPle. It has been claimed that, as belonging to the class
of defensins, HNP1 can deactivate the enveloped virus by inter-
acting with GAGs present on the viral surface, altering the ability
of these glycoproteins to bind to their receptors at the target
cells. Moreover, this peptide has also been shown to stimulate the
immune modulatory system of infected fish cells by modulating
IFN-related mechanisms (Falco et al., 2007, 2009).
ANTIVIRAL PEPTIDE DRUGS APPLIED TO AGRICULTURE
Cationic antivirus peptides may also be applied to plant pro-
tection against viruses that cause diseases in crops. Among the
various symptoms of viral infections in plants, stunting, mosaic
patterns, yellowing, leaf rolling, ring spot, necrosis, wilting, and
other developmental abnormalities can be observed (Hull, 2002).
These symptoms consequently cause a decrease in production
leading to economic losses. Strategies to combat viral diseases in
plants are usually directed to the prevention or reduction of infec-
tion which may have, however, adverse effects on human health
and the environment. Therefore, AMPs have become promis-
ing alternatives for protecting crops against viral diseases while
simultaneously protecting human health and the environment.
A cyclic peptide of 7 amino acid residues called peptamine
from Pseudomonas chlororaphis O6 has shown antiviral activ-
ity against the tobacco mosaic virus (TMV). Antiviral bioassays
of tobacco plants suppressed 95% of TMV disease. The mode
of action by which peptamine suppresses the disease is still
unknown, but it has been speculated that this peptide may induce
systemic resistance against TMV (Park et al., 2012). The pep-
tide PAP, a ribosome inactivating protein (RIP) isolated from
Phytolacca americana, was highly effective in inhibiting the for-
mation of local lesions caused by TMV on tobacco leaves (Taylor
et al., 1994). RIPs are known to cause damage to ribosomes
by removing adenine residues from 28S rRNA through an N-
glycosidase activity, and the removal of this base prevents binding
of the elongation factor 2 (EF-2), consequently stoping the syn-
thesis of proteins (Kaur et al., 2011). Another cationic antiviral
with activity against TMV is subK7I, a synthetic analog of melit-
tin. This peptide has sequence and structural similarity to an
essential domain of the TMV coat protein and was found to pos-
sess highly specific antiviral activity. Bioassays of tobacco leaves
upon addition of the analog to the solution before inoculation
of the virus has demonstrated a reduction of more than 90% of
infectivity of TMV with dependent doses (Marcos et al., 1995).
Tripathi and colleagues isolated a small antiviral peptide of
5.57 kDa called potide-G from potato tubers resistant to Potato
Virus Y (PVY). Results of real-time PCR showed that the appli-
cation of 10μg of purified potide-G was sufficient to reduce
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virus accumulation by 50% on average from the PVY infection in
susceptible “Winter Valley” cultivars. The authors have reported
that this peptide isolated from resistant potatoes offers new
opportunities for the development of new biological pesticides
against plant viruses (Tripathi et al., 2006).
PRODUCTION OF CATIONIC ANTITUMOR AND
ANTIVIRAL PEPTIDES
While peptides have great potential for use in antitumor drugs,
there are some limitations that need to be addressed. It is well-
known that they can be used in a number of different ways in
treating cancer such as vaccines, hormones, tumor targeting with
cytotoxic drugs and radioisotopes, and anti-angiogenic peptides
(Thundimadathil, 2012). Currently, there are about 60 approved
peptide drugs on the market and it is expected to reach an esti-
mated $12 billion USD in sales by the end of 2013 (Pichereau
and Allary, 2005). All of these investments have resulted in more
than 100 peptide-based drugs which are already available on the
global market, representing about 1.5% of all drug sales (Lax,
2010; Craik et al., 2013). Out of four peptide drugs on the mar-
ket which have reached global sales over $1 billion USD, three
peptides are used in treating cancer directly or in the treatment
of episodes associated with certain tumors: leuprolide acetate
(Lupron; $2.12 billion), goserelin acetate (Zoladex; $1.14 bil-
lion), and octreotide acetate (Sandostatin; $1.12 billion) (Reichert
et al., 2010; Thundimadathil, 2012). Mendoza and colleagues
have summarized approximately 30 peptides which were discov-
ered/developed as peptide-based anticancer drugs in order to
provide foundations for therapies (Mendoza et al., 2005).
However, when it comes to the market of AMPs as antitu-
mor drugs, the scenario is much different. Although over 1000
potential therapeutic AMPs have been isolated and characterized
from different sources, only limited success has been achieved in
clinical trials (Hu et al., 2011).
There are currently only around ten AMPs in either preclinical
or clinical trial phases (Fox, 2013) and few of these present antitu-
mor activity. Their major limitations are the poor bioavailability
due to their instability and insolubility related to the intrinsic
physicochemical properties, potential toxicity to host cells, tis-
sue distribution, poor pharmacokinetic issues, and the cost of
large scale production (Rotem and Mor, 2009; Hu et al., 2011).
Despite these disadvantages, antitumor peptides have potential
due to their high specificity and potency against malignant cells.
Therefore, numerous studies have been performed in order to
improve their bioavailability and reduce their cost of production.
Much effort has been put into the mimicry of antitumor pep-
tides to alter their features in order to achieve robustness and
safety. These approaches have become important and promis-
ing for improving the therapeutic potential of antitumor peptides
(Rotem and Mor, 2009).
HDP mimicry has been performed by constructing oligomers
of acyl-lysyl and/or lysyl-acyl-lysyl (OAKs), which has turned
out to be the first designed system to show antitumor potential
in vivo. This system was able to translocate across the mem-
brane and interact with multiple intracellular targets, including
mitochondria, especially the inner membrane which contains a
relatively high portion of negatively-charged phospholipids that
might mediate interactions with these HDPs. Moreover, it was
associated with an improved toxicity profile when compared to
doxorubicin, an anthracycline antibiotic used in chemotherapy.
It has also been observed that local administration of both OAK
and doxorubicin resulted in a complete disappearance of tumors
in 50% of treated mice, while in the remaining 50% tumors were
minuscule, thereby suggesting that the synergic effect of this ther-
apy was both potent and well tolerated. The OAKmight also dam-
age lysosome structure and/or interfere with the function of 50
hydrolases that normally process the cell’s major macromolecules
(Held-Kuznetsov et al., 2009).
In another study, sequence optimization and modification
based on natural peptide sequences and traits was performed and
it has shown that the system G(IIKK)nI-NH 2 (being n = 3 − 4)
was effective against HeLa and HL60 cancer cell lines with 50%
growth inhibition concentrations (Hu et al., 2011). Mai and col-
leagues have designed a novel antitumor peptide, DP1, derived
from a synthetic AMP that significantly induces apoptosis in solid
tumors by local injection. It was composed of a protein trans-
duction domain (PTD), PTD-5, fused to the AMP KLAKLAK2,
an antimicrobial apoptosis-inducing peptide that upon inter-
nalization causes mitochondrial swelling and disruption of the
mitochondrial membrane leading to apoptosis (Mai et al., 2001;
Thundimadathil, 2012).
Rational design of novel peptides has also been performed to
create six analogs of temporin-1CEa, a naturally occurring α-
helical and amphipathic AMP derived from skin secretions of
the Chinese brown frog Rana chensinensis (Yang et al., 2013).
These analogs were synthesized with either increased cationicity
or increased/decreased hydrophobicity generally by substituting
neutral and acidic amino acids with lysine or leucine residues
on the polar face and non-polar face of the α-helix in order to
evaluate the correlation between anticancer activity and physical
properties of these peptides. All peptides showed potent anti-
cancer activities against three cancer cell lines (MCF-7, Bcap-37,
and MDA-MB-231). This study has suggested that the strategy of
increasing the cationicity and keeping moderate hydrophobicity
of naturally occurring AMPs is suitable to improve their cyto-
toxicity against tumor cells and decrease their hemolytic activity
(Yang et al., 2013).
Synthetic links between two functional domains, an AMP
(KLAKLAKKLAKLA K) and the isoDGR, (isoAsp-Gly-Arg), a
derivative of a targeted delivery tool, was performed to construct
a novel antitumor peptide. It was shown that this novel construc-
tion can selectively kill CD13−/αvβ3+ breast cancer cells in both
in vitro and in vivo experiments. The mechanism of action was
claimed to inhibit angiogenesis by binding to αvβ3+ which is up-
regulated on tumor cells and tumor endothelial cells (Hou et al.,
2013).
These studies strongly suggest that the peptidomimetics is a
potent tool for developing new antitumor peptides. Moreover,
these molecules may have their potential increased when it func-
tions as an adjuvant therapy in conjunction with radiotherapy,
chemotherapy, or surgical procedures.
When antiviral therapy is considered, the major barriers to the
development and use of effective therapy are the current expen-
sive approaches to impairing the completion of the viral growth
cycle in the infected cell without being toxic to the surround-
ing normal cells, and diagnosing the viral disease before it is too
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late for effective therapy. It has also been claimed that the rea-
son for the lack of progress in antiviral therapy is the selectivity,
since the viruses are functionally incorporated into the host cells,
and therefore it is difficult to select a proper tag (Kinchington
et al., 1995; Abonyi et al., 2009). Furthermore, a relevant bar-
rier is applied to the market of antivirus drugs, which concentrate
efforts on a few viruses. It is known that out of 60 antiviral
drugs that have thus far been approved by the US Food and
Drug Administration (FDA), almost half of them target HIV-
1 with the remaining half used for the treatment of HBV and
HCV infections, HSV, CMV, varicella-zoster virus (VZV), and
influenza (IAV) (De Clerq, 2008; Findlay et al., 2013). There are
currently 15 peptide-based strategies against viruses in differ-
ent stages of clinical trials as candidates for therapeutic drugs
against many viruses (Thakur et al., 2012). However, none are
cationic antiviral peptides, although reports of their high activ-
ity are exciting enough to include them as potential candidates, as
is the case of alloferon. It has been shown that preventive and/or
therapeutic administration of alloferon essentially increased the
survival rate and suppressed virus reproduction in mice intra-
cerebrally infected with HSV-2. Alloferon-based therapy of HSV,
HBV, andHCV infections is now under extensive preclinical study
(Chernysh et al., 2002).
Synthetic analogs of several naturally occurring AMPs have
been made in attempt to identify important structural fea-
tures contributing to their antiviral activity as well as to opti-
mize these molecules in order to develop the shortest, cheapest,
most stable and functional molecules at lower concentrations
(Jenssen et al., 2006). Recently, the first antivirus peptide pre-
diction method, based on the collected peptides which were
experimentally proven for antiviral activity, was developed and
named AVPpred (Thakur et al., 2012). This method is specific
for antivirus peptides, where 25 physicochemical properties to
develop antivirus peptide-physico models, amino acid composi-
tion, and sequence alignment implementing BLASTP algorithms
for prediction of AVPs were used.
HETEROLOGOUS PRODUCTION OF ANTITUMOR AND ANTIVIRAL
CATIONIC PEPTIDES
Beyond the use of peptide mimicry to develop synthetic peptides,
the advance in the use of heterologous systems for produc-
tion of cationic peptides has been a promising alternative.
Many groups have been performing recombinant technology
in order to optimize the production yield of cationic pep-
tides using animal cells (Brocal et al., 2006), yeast (Wang
et al., 2009b), plant (Lee et al., 2011), and bacteria systems
(Wang et al., 2011).
For instance, the expression and purification of the recom-
binant human α-defensin 5 has been performed in Pichia pas-
toris, and it has been reported that this peptide was functionally
expressed and it showed in vitro activity to block human papil-
lomavirus infection (Wang et al., 2009b). The housefly cecropin
peptide has also been expressed in this organism, however, nei-
ther antiviral nor antitumor activities have been tested in this
specific system (Jin et al., 2006). The lack of both activity could
also be observed for the expression of the peptide pleurocidin,
which has been expressed in both yeast (Burrowes et al., 2005)
and fish cell lines (Brocal et al., 2006), although only in the latter
case antibacterial activity was tested.
The concept of plant-made biopharmaceuticals has also been
lately explored for the expression of antiviral cationic peptides.
For example, the peptide retrocyclin, an important AMP which
can be used as therapeutic agent against HIV-1 viral infec-
tions, have been expressed and characterized in tobacco chloro-
plasts genome, and its antiviral activity was confirmed against
TMV infection (Lee et al., 2011). The peptide cecropin was also
expressed in both camelina (Camelina sativa) (Zakharchenko
et al., 2013) and tomato (Solanum lycopersicum) (Jan et al., 2010).
Nevertheless, in these studies the tests performed did not include
antiviral or antitumor activities.
The most common organism for construction of heterolo-
gous expression systems is bacteria, and E. coli is the most used
(Parachin et al., 2012). This bacterium has been used for expres-
sion of cecropin (Liang et al., 2006), lactoferricin (Luo et al.,
2007), human α and β defensins (Wang et al., 2010b), buforin
(Wang et al., 2011), indolicin (Morin et al., 2006), and LL-37
(Moon et al., 2006). Two different systems for expression of
cecropin, one fused to enterokinase (Xu et al., 2007a) and other
hybrid system fused to ubiquitin (Xu et al., 2007b) were con-
structed, and both systems were active against Gram-positive and
negative bacteria, and fungi. Another two hybrid systems have
also been constructed to actively express the peptide lactoferricin
(Kim et al., 2006; Feng et al., 2011). Furthermore, many bioactive
human defensin have been successfully expressed in E. coli such
as the human α-defensin 6, which showed to inhibit HSV-2 infec-
tion (Wang et al., 2010b), the β-defensin 5 and 6 (Huang et al.,
2008), the β-defensin 26 and 27 (Huang et al., 2009), β-defensin
2 (Zhong et al., 2006), and β-defensin 4 (Xu et al., 2006; Li et al.,
2010).
As shown above, many studies have shown that the heterol-
ogous expression of cationic peptides is feasible, and in many
cases, depending on their size and structure, is a better alternative
for production of pharmaceuticals than the synthetic synthe-
sis (Parachin et al., 2012). However, none of the studies cited
above have optimized the large-scale production of the pep-
tides expressed. Doubtless it is important to mention that many
efforts have been made to efficiently develop or improve the cost-
effective methodology (e.g., new expression systems and opti-
mized fermentation processes) for production of AMPs, as well
as to overcome barriers involving both recombinant technology
processes and the economic scenario of biotechnology and phar-
maceutical companies in order to change the drug-development
current scenario.
NANOFORMULATION AS DRUG-DELIVERY SYSTEM
In order to overcome the restraints to the use of cationic peptides
described above, nanoformulation techniques have emerged as a
potent biological tool to improve the delivery and stability and of
these molecules.
The primary goals of drug delivery for cancer therapy is to
improve the therapeutic index of anticancer drugs by increasing
the amount of drug delivered to the tumor site and decreasing
its exposure to healthy tissues (McDaniel et al., 2010). Several
microencapsulation technologies have been developed for use
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in the pharmaceutical industry, such as hydrogels, liposomes,
nanoemulsions, and nanoparticles (Onwulata, 2012). Therefore,
the development and improvement of nanoparticles have shown
great promise to overcome the delivery barriers of pharmaceuti-
cals (Zhang et al., 2012).
Recently Wang and Zhang (2013) encapsulated a CPAP, a
dose-dependent antiproliferation peptide and inducer of the
post-G1 cell cycle arrest in gastric cancer cells. Two methods
were used: complex coacervation (edible alginate, CaCl2 and chi-
tosan involved) to perform a microencapsulation of CPAP, and
ionotropic gelation (edible chitosan and sodium tripolyphos-
phate involved) to perform a nanoencapsulation process. The
former refers to the phase separation of a liquid precipitate/phase
when solutions of two hydrophilic colloids are mixed under
suitable conditions, and the latter is based on the ability of poly-
electrolyte counter ions to cross link to form hydrogels (Wang and
Zhang, 2013). Their results demonstrated that the encapsulation
efficiency of microencapsulation (74.5%) is much greater than
that of nanoencapsulation (30.1%), but their polypeptides con-
tents are similar (12.7 vs. 12.3%). The in vitro release tests revealed
that CPAP was well-preserved against gastric enzymatic degra-
dation after micro/nanoencapsulation and the slowly-controlled
release in the intestine could be achieved. Although further in
vivo studies are required to verify these findings, this study has
provided a basis for the development of encapsulated antitumor
peptides (Wang and Zhang, 2013).
Another study has performed encapsulation of an antitumor
peptide in order to develop an effective gene-modified tumor
cell vaccine. In this study, the gene of interleukin-27 (IL-27), a
novel IL-6/IL-12 family cytokine, was transfected in LL/2 (Lewis
lung cancer cell) by using a cationic liposome. This resultant
tumor cell vaccine then containing both tumor associated anti-
gen (TAA) of LL/2 cells and secreted mIL-27 (mouseIL-27) at a
relative high level, could induce protective antitumor immunity
in mice, which was claimed to be an attribute of high-cytokine
production achieved by the liposome-DNA complex. It was also
observed that LL/2-mIL-27 cell vaccine up-regulated IFN-γ in
serum and improved local CD4+ and CD8+ T cell infiltration in
mice. This study shows an important and promising strategy for
AMP-based therapeutic approach against tumors (Zhang et al.,
2013b).
Regarding cationic antiviral peptides, a nanoformulation tech-
nique has also been studied as a potent bio-tool to improve their
delivery and stability. Nanoformulation of the amphiphatic α-
helical peptide p41, a positively-charged analog of C5A peptide
derived from the HCV protein, was performed to treat HIV/HCV
co-infection. The cationic antiviral peptide was incorporated into
anionic poly (amino acid)-based block copolymers prepared via
eletrostetic coupling. The nanocomplexes were ca. 35 nm in size,
stable at physiological pH and ionic strength. The in vitro antivi-
ral activity against both HCV and HIV was retained and their
intrinsic cytotoxicity was attenuated. The in vivo APN were able
to decrease the viral load in mice transplanted with human lym-
phocytes and HIV-1-infected. Overall, these findings indicate
the potential of these formulations for stabilization and delivery
of antiviral peptides while maintaining their functional activity
(Zhang et al., 2013a).
CONCLUDING REMARKS
Many natural cationic peptides from the immense biodiversity
of several groups of organisms have been isolated and have
demonstrated great potential as antiviral and antitumor agents.
Furthermore, the development of novel synthetic analogs of these
natural molecules has been an important biological tool for
enhancing their activities and facilitating the screening process for
new natural AMPs. Studies on antitumor and/or antiviral AMPs
have demonstrated that these molecules work as excellent ther-
apeutic agents and even lead to greater success when combined
with traditional treatments. The number of antitumor and/or
antiviral AMPs has been increasing and is expected to lead to a
change in their current scenario, from their entry into clinical trial
to their availability on the market. A crucial step for this change
to occur is to continue researching and identifying their mecha-
nisms of action and to discover new targets, followed by studies
on developing new potential delivery systems.
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